Sinopec Engineering Group (2386.HK): Key takeaways from 2017 results
机构:中金公司
评级:BUY
目标价:9.70港元
Recurring profit in line with expectation
Sinopec Engineering Group (SEG) announced FY17 results: Revenue down 8% to Rmb36.2bn; reported earnings down 32% to Rmb1.13bn (Rmb0.26/sh) but up 16% to Rmb1.9bn (vs our Rmb2.0bn forecast) excluding one-off items such as a Rmb666mn forex loss and Rmb96mn in receivables provisioning. Dividend payout ratio rose to 79%; DPS of Rmb0.20 implies yield of more than 3% based on today’s close. Management is confident payout ratio will remain above 40%.
Trends to watch
New order target for FY18 appears conservative. Management is targeting new contracts worth more than Rmb48bn in FY18, with Rmb38bn from domestic projects, including Rmb19.6bn from the newly announced Zhongke integrated refining and petrochemical project. We are more optimistic and believe SEG can win Rmb55– 60bn worth of orders.
LNG potential. Management believes SEG will benefit from the ongoing natural gas boom. In particular, Sinopec has a series of LNG projects, including a new terminal in Wenzhou (Zhejiang Province), a capacity expansion project for the Tianjin receiving terminal, and the Alaska LNG project in the US. Investment from private players in gas storage facilities in China are also potential new revenue sources.
Margin trends also positive. As higher margin domestic projects may dominate revenue booking in FY18 and FY19, management expects gross margin to improve from 2H17’s low. Cost cutting may further enhance net margin.
Earnings forecast
We maintain our earnings forecasts.
Valuation and recommendation
The stock is trading at 8x 2019e P/E. We maintain our target price of HK$9.7 (10x 2019e P/E) and BUY rating.
Risks
Project delays, less than expected clients, FX risks
- 提价逻辑或将成为红利资产超越“高股息”以外新支撑
- 风口上的猪!4月销售简报8家上市公司全部环比上涨,资产负债表优先修复企业有望受益
- 银行网点与保险公司合作数量限制取消,利好银行降低“存贷息差”、增加保险代理收入
- 性能全面赶超GPT-4-Turbo中文大模型来了,国内模型持续超预期有望带动投资者信心提升
- 锑锭价格创出近十年来新高,有色金属板块或将迎来超额收益
- 4月份挖掘机销量好于预期,机构看好海外市场潜力
- 一季报披露完毕医药板块“利空出尽”,创新药或成当前医药行情的矛
- 静注人免疫球蛋白价格猛涨且缺货严重,关注头部血制品企业
- 锰相关期货近期持续走强,澳大利亚锰矿供应缺口或持续到第三季度中期
- 今年度夏期间全国用电负荷还将快速增,火力发电地位不变煤炭需求将持续有保障